Welcome to our dedicated page for Medicure news (Ticker: MCUJF), a resource for investors and traders seeking the latest updates and insights on Medicure stock.
Medicure Inc. reports developments tied to its U.S. pharmaceutical commercialization business, pharmacy operations, research programs, and public-company governance. The company markets and distributes AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets through its U.S. subsidiary, Medicure Pharma Inc., and operates pharmacy businesses including Marley Drug, Gateway Medical Pharmacy, and West Olympia Pharmacy.
Recurring updates include quarterly and annual financial results, product revenue from AGGRASTAT and ZYPITAMAG, pharmacy revenue, research and development spending, and the MC-1 program for PNPO deficiency. News also covers completed pharmacy acquisitions, shareholder meeting results, conference calls, and executive leadership changes.
Medicure has entered into a License, Manufacture and Supply Agreement with Reliance Life Sciences for a cardiovascular biosimilar. This deal grants Medicure exclusive rights to market the product in the U.S., Canada, and the European Union. Medicure will oversee the regulatory approval process. CEO Dr. Albert Friesen expressed optimism about growing their cardiovascular portfolio. The partnership aims to enhance Medicure's market positioning and revenue potential in the cardiovascular segment.
Medicure Inc. (OTC: MCUJF) has reported promising early clinical findings for AGGRASTAT® (tirofiban hydrochloride) in the treatment of thrombotic complications associated with COVID-19. A small proof of concept study showed significant improvements in oxygen levels in patients treated with AGGRASTAT® alongside standard care. The company plans to evaluate further randomized clinical studies in the U.S. to confirm efficacy and safety for COVID-19 patients. Importantly, AGGRASTAT® is not currently approved for COVID-19 treatment nor claims to eliminate the virus.
Medicure has terminated its marketing agreement with Sensible Medical Innovations for the ReDS Pro™ device in the U.S. The decision aligns with a strategic review and allows Medicure to concentrate on its own higher-margin products, AGGRASTAT® and ZYPITAMAG™. The termination includes a transition agreement that provides additional compensation for customer leads to Medicure. Medicure retains a 7.71% equity interest in Sensible, indicating ongoing support for the company during its transition.